|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
ophthalmologist
|
|
gptkbp:approvalYear
|
2004
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
S01LA03
|
|
gptkbp:CASNumber
|
265934-87-8
|
|
gptkbp:category
|
anti-VEGF agent
ophthalmology drug
|
|
gptkbp:developer
|
gptkb:Pfizer
gptkb:Eyetech_Pharmaceuticals
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:genericName
|
gptkb:pegaptanib
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Macugen
|
|
gptkbp:indication
|
gptkb:neovascular_(wet)_age-related_macular_degeneration
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
aptamer
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
gptkb:Eyetech_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
VEGF inhibitor
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
DB00082
|
|
gptkbp:routeOfAdministration
|
intravitreal injection
|
|
gptkbp:sideEffect
|
eye pain
increased intraocular pressure
intraocular inflammation
punctate keratitis
vitreous floaters
|
|
gptkbp:target
|
VEGF165 isoform
|
|
gptkbp:UNII
|
Q1Q0PML3XP
|
|
gptkbp:usedFor
|
age-related macular degeneration
|
|
gptkbp:bfsParent
|
gptkb:Eyetech_Inc.
gptkb:Aptamers
gptkb:pegaptanib
|
|
gptkbp:bfsLayer
|
7
|